Multiplexed cytokine profiling of serum for detection of colorectal cancer

Future Oncology

Volumn 9, Issue 7, 2013, Pages 1017-1027

  Pengjun, Zhang ^a   Xinyu, Wen ^a   Feng, Gu ^a   Xinxin, Deng ^a   Yulan, Liu ^a   Juan, Li ^a   Xingwang, Jia ^a   Zhennan, Dong ^a   Yaping, Tian ^a,b  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b NANKAI UNIVERSITY   (China)

Author keywords

biomarker; colorectal adenoma; colorectal cancer; cytokine; serum

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKINE; GAMMA INTERFERON; GELATINASE A; GELATINASE B; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; MATRILYSIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; ASCENDING COLON; CANCER DIAGNOSIS; CANCER SCREENING; CECUM; COLORECTAL ADENOMA; COLORECTAL CANCER; CONTROLLED STUDY; DESCENDING COLON; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECTUM; SENSITIVITY AND SPECIFICITY; SIGMOID; TRANSVERSE COLON; TREATMENT RESPONSE;

ADENOMA; ADULT; AGED; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; AREA UNDER CURVE; CARCINOEMBRYONIC ANTIGEN; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; CYTOKINES; FEMALE; HUMANS; INTERLEUKIN-8; LOGISTIC MODELS; MALE; MATRIX METALLOPROTEINASE 7; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84880233927     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.71     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J. Clin. 59(4), 225-249 (2009).
2. Muller AD, Sonnenberg A. Prevention of colorectal cancer by flexible endoscopy and polypectomy. A case-control study of 32,702 veterans. Ann. Intern. Med. 123(12), 904-910 (1995).
3. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J. Clin. 51(1), 15-36 (2001).
4. Kim HJ, Yu MH, Kim H, Byun J, Lee C. Noninvasive molecular biomarkers for the detection of colorectal cancer. BMB Rep. 41(10), 685-692 (2008).
5. Miller S, Steele S. Novel molecular screening approaches in colorectal cancer. J. Surg. Oncol. 105(5), 459-467 (2012).
6. Messenger DE, Driman DK, Kirsch R. Developments in the assessment of venous invasion in colorectal cancer: Implications for future practice and patient outcome. Hum. Pathol. 43(7), 965-973 (2012).
7. Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res. 66(11), 5527-5536 (2006).
8. Ben-Baruch A. Inflammation-associated immune suppression in cancer: The roles played by cytokines, chemokines and additional mediators. Semin. Cancer Biol. 16(1), 38-52 (2006).
9. Karin M, Greten FR. NF-kappaB: Linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 5(10), 749-759 (2005).
10. Coussens LM, Werb Z. Inflammation and cancer. Nature 420(6917), 860-867 (2002).
11. Belardelli F, Ferrantini M. Cytokines as a link between innate and adaptive anti-tumor immunity. Trends Immunol. 23(4), 201-208 (2002).
12. Wright H, Alex P, Nguyen T et al. Multiplex cytokine profiling of initial therapeutic response in patients with chronic hepatitis C virus infection. Dig. Dis. Sci. 50(10), 1793-1803 (2005).
13. Kraus TA, Sperling RS, Engel SM et al. Peripheral blood cytokine profiling during pregnancy and post-partum periods. Am. J. Reprod. Immunol. 64(6), 411-426 (2010).
14. Bobe G, Murphy G, Albert PS et al. Serum cytokine concentrations, flavonol intake and colorectal adenoma recurrence in the Polyp Prevention Trial. Br. J. Cancer 103(9), 1453-1461 (2010).
15. Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: A comprehensive cytokine profiling study. J. Clin. Oncol. 29(10), 1356-1363 (2011).
16. Szkaradkiewicz A, Marciniak R, Chudzicka-Strugala I et al Proinflammatory cytokines and IL-10 in inflammatory bowel disease and colorectal cancer patients. Arch. Immunol. Ther. Exp. (Warsz) 57(4), 291-294 (2009).
17. Slattery ML, Lundgreen A, Bondurant KL, Wolff RK. Interferon-signaling pathway: Associations with colon and rectal cancer risk and subsequent survival. Carcinogenesis 32(11), 1660-1667 (2011).
18. Knupfer H, Preiss R. Serum interleukin-6 levels in colorectal cancer patients - a summary of published results. Int. J. Colorectal Dis. 25(2), 135-140 (2010).
19. Kaminska J, Nowacki MP, Kowalska M et al. Clinical significance of serum cytokine measurements in untreated colorectal cancer patients: Soluble tumor necrosis factor receptor type I - an independent prognostic factor. Tumour Biol. 26(4), 186-194 (2005).
20. Harrison ML, Obermueller E, Maisey NR et al. Tumor necrosis factor alpha as a new target for renal cell carcinoma: Two sequential Phase II trials of infliximab at standard and high dose. J. Clin. Oncol. 25(29), 4542-4549 (2007).
21. Zucker S, Vacirca J. Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev. 23(1-2), 101-117 (2004).
22. Kellar KL, Douglass JP. Multiplexed microsphere-based fcytometric immunoassays for human cytokines. J. Immunol. Methods 279(1-2), 277-285 (2003).
23. Giavedoni LD. Simultaneous detection of multiple cytokines and chemokines from nonhuman primates using Luminex technology. J. Immunol. Methods 301(1-2), 89-101 (2005).
24. Terhaar Sive Droste JS, Oort FA, van der Hulst RW et al. Does delay in diagnosing colorectal cancer in symptomatic patients affect tumor stage and survival? A population-based observational study. BMC Cancer 10, 332 (2010).
25. Lin YC, Mahalingam J, Chiang JM et al. Activated but not resting regulatory T cells accumulated in tumor microenvironment and correlated with tumor progression in patients with colorectal cancer. Int. J. Cancer 132(6), 1341-1350 (2012).
26. Yehuda-Shnaidman E, Schwartz B. Mechanisms linking obesity, inflammation and altered metabolism to colon carcinogenesis. Obes. Rev. 13(12), 1083-1095 (2012).
27. Dong W, Li H, Zhang Y et al. Matrix metalloproteinase 2 promotes cell growth and invasion in colorectal cancer. Acta Biochim. Biophys. Sin. (Shanghai) 43(11), 840-848 (2011).
28. Suboj P, Babykutty S, Valiyaparambil Gopi DR, Nair RS, Srinivas P, Gopala S. Aloe emodin inhibits colon cancer cell migration/angiogenesis by downregulating MMP-2/9, RhoB and VEGF via reduced DNA binding activity of NF-kappaB. Eur. J. Pharm. Sci. 45(5), 581-591 (2012).
29. Kuang L, Wang L, Wang Q et al. Cudratricusxanthone G inhibits human colorectal carcinoma cell invasion by MMP-2 down-regulation through suppressing activator protein-1 activity. Biochem. Pharmacol. 81(10), 1192-1200 (2011).
30. Babykutty S, Suboj P, Srinivas P, Nair AS, Chandramohan K, Gopala S. Insidious role of nitric oxide in migration/invasion of colon cancer cells by upregulating MMP-2/9 via activation of cGMP-PKG-ERK signaling pathways. Clin. Exp. Metastasis 29(5), 471-492 (2012).
31. Dragutinovic VV, Radonjic NV, Petronijevic ND et al. Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) in preoperative serum as independent prognostic markers in patients with colorectal cancer. Mol. Cell. Biochem. 355(1-2), 173-178 (2011).
32. Groblewska M, Mroczko B, Gryko M, Kedra B, Szmitkowski M. Matrix metalloproteinase 2 and tissue inhibitor of matrix metalloproteinases 2 in the diagnosis of colorectal adenoma and cancer patients. Folia Histochem. Cytobiol. 48(4), 564-571 (2010).
33. Peng ZH, Wan DS, Li LR et al. Expression of COX-2, MMP-2 and VEGF in stage II and III colorectal cancer and the clinical significance. Hepatogastroenterology 58(106), 369-376 (2011).
34. Lee CM, Jang D, Cheong SJ et al. Optical imaging of MMP expression and cancer progression in an inflammation-induced colon cancer model. Int. J. Cancer 131(8), 1846-1853 (2012).
35. Lee YS, Choi I, Ning Y et al. Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis. Br. J. Cancer 106(11), 1833-1841 (2012).
36. Berghella AM, Contasta I, Pellegrini P, Del Beato T, Adorno D. Peripheral blood immunological parameters for use as markers of pre-invasive to invasive colorectal cancer. Cancer Biother. Radiopharm. 17(1), 43-50 (2002).
37. Ning Y, Manegold PC, Hong YK et al. Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. Int. J. Cancer 128(9), 2038-2049 (2011).
38. Kargi A, Yalcin AD, Erin N, Savas B, Polat HH, Gorczynski RM. IL8 and serum soluble TRAIL levels following anti-VEGF monoclonal antibody treatment in patients with metastatic colon cancer. Clin. Lab. 58(5-6), 501-505 (2012).
39. Hwang WL, Yang MH, Tsai ML et al. SNAIL regulates interleukin-8 expression, stem cell-like activity, and tumorigenicity of human colorectal carcinoma cells. Gastroenterology 141(1), 279-291, 291 e271-e275 (2011).
40. Landi S, Moreno V, Gioia-Patricola L et al. Association of common polymorphisms in infgenes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res. 63(13), 3560-3566 (2003).
41. Hammer JH, Nielsen HJ, Moesgaard F, Kehlet H. Duration of postoperative immunosuppression assessed by repeated delayed type hypersensitivity skin tests. Eur. Surg. Res. 24(3), 133-137 (1992).
42. Heriot AG, Marriott JB, Cookson S, Kumar D, Dalgleish AG. Reduction in cytokine production in colorectal cancer patients: Association with stage and reversal by resection. Br. J. Cancer 82(5), 1009-1012 (2000).
43. Luo JL, Maeda S, Hsu LC, Yagita H, Karin M. Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell 6(3), 297-305 (2004).
44. Elgert KD, Alleva DG, Mullins DW. Tumor-induced immune dysfunction: The macrophage connection. J. Leukoc. Biol. 64(3), 275-290 (1998).
45. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest. 117(5), 1175-1183 (2007).
46. Koskensalo S, Louhimo J, Nordling S, Hagstrom J, Haglund C. MMP-7 as a prognostic marker in colorectal cancer. Tumour Biol. 32(2), 259-264 (2011).
47. Yoshimoto M, Itoh F, Yamamoto H, Hinoda Y, Imai K, Yachi A. Expression of MMP-7(PUMP-1) mRNA in human colorectal cancers. Int. J. Cancer 54(4), 614-618 (1993).
48. Luo HZ, Zhou ZG, Yang L et al. Clinicopathologic and prognostic significance of MMP-7 (matrilysin) expression in human rectal cancer. Jpn J. Clin. Oncol. 35(12), 739-744 (2005).
49. Nastase A, Paslaru L, Niculescu AM et al. Prognostic and predictive potential molecular biomarkers in colon cancer. Chirurgia (Bucur.) 106(2), 177-185 (2011).
50. Kioi M, Yamamoto K, Higashi S, Koshikawa N, Fujita K, Miyazaki K. Matrilysin (MMP-7) induces homotypic adhesion of human colon cancer cells and enhances their metastatic potential in nude mouse model. Oncogene 22(54), 8662-8670 (2003).